In the Claims

1.- 42. (Canceled)

- 43. (Currently Amended) A pharmaceutical composition comprising:
- a therapeutically effective amount of an antigen presenting cell pulsed with an inactivated non-recombinant human immunodeficiency virus (HIV); and

a pharmaceutically acceptable carrier;

wherein the inactivated human immunodeficiency virus is chemically inactivated by 2,2'-dithiopyridine, and wherein the composition expands in vivo expression of virus-specific CD8+ T cells, and said virus-specific CD8+ cells kill HIV-infected cells.

- 44. (Previously presented) The pharmaceutical composition of Claim 43, wherein said inactivated human immunodeficiency virus is an inactivated autologous human immunodeficiency virus.
- 45. (Previously presented) The pharmaceutical composition of Claim 43, wherein said antigen-presenting cell is a dendritic cell.
- 46. (Previously presented) The pharmaceutical composition of Claim 45, wherein said dendritic cell is an autologous dendritic cell.
- 47. (Previously presented) The pharmaceutical composition of Claim 45, wherein the dendritic cell is a monocyte-derived dendritic cell.

48.-50. (Cancelled)

- 51. (Currently Amended) The pharmaceutical composition of Claim 48 43, wherein the inactivated human immunodeficiency virus is an inactivated autologous human immunodeficiency virus.
- 52. (New) The pharmaceutical composition of claim 43, further comprising an adjuvant for optimizing the virus-specific CTL response.

- 53. (New) The pharmaceutical composition of claim 52, wherein said adjuvant is a protease inhibitor.
- 54. (New) The pharmaceutical composition of claim 53, wherein said protease inhibitor is indinavir.
- 55. (New) The pharmaceutical composition of claim 54, wherein said composition comprises non-antiviral concentration of indinavir.
- 56. (New) The pharmaceutical composition of claim 55, comprising a concentration of indinavir of about 10 nM.